ANDREWS, P.W., D. BAKER, N. BENVINISTY, B. MIRANDA, K. BRUCE, O. BRUSTLE, M. CHOI, Y.M. CHOI, J.M. CROOK, P.A. de SOUSA, Petr DVOŘÁK, C. FREUND, M. FIRPO, M.K. FURUE, P. GOKHALE, H.Y. HA, E. HAN, S. HAUPT, L. HEALY, D.J. HEI, O. HOVATTA, C. HUNT, S.M. HWANG, M.S. INAMDAR, R.M. ISASI, M. JACONI, V. JEKERLE, P. KAMTHORN, M.C. KIBBEY, I. KNEZEVIC, B.B. KNOWLES, S.K. KOO, Y. LAABI, L. LEOPOLDO, P. LIU, G.P. LOMAX, J.F. LORING, T.E. LUDWIG, K. MONTGOMERY, C. MUMMERY, A. NAGY, Y. NAKAMURA, N. NAKATSUJI, S. OH, S.K. OH, T. OTONKOSKI, M. PERA, M. PESCHANSKI, P. PRANKE, K.M. RAJALA, M. RAO, R. RUTTACHUK, B. REUBINOFF, L. RICCO, H. ROOKE, D. SIPP, G.N. STACEY, H. SUEMORI, T.A. TAKAHASHI, K. TAKADA, S. TALIB, S. TANNENBAUM, B.Z. YUAN, F. ZENG and Q. ZHOU. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). REGENERATIVE MEDICINE. LONDON: FUTURE MEDICINE LTD, 2015, vol. 10, No 2, p. 1-44. ISSN 1746-0751. Available from: https://dx.doi.org/10.2217/RME.14.93.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)
Authors ANDREWS, P.W. (826 United Kingdom of Great Britain and Northern Ireland), D. BAKER (826 United Kingdom of Great Britain and Northern Ireland), N. BENVINISTY (376 Israel), B. MIRANDA (724 Spain), K. BRUCE (826 United Kingdom of Great Britain and Northern Ireland), O. BRUSTLE (276 Germany), M. CHOI (410 Republic of Korea), Y.M. CHOI (410 Republic of Korea), J.M. CROOK (36 Australia), P.A. de SOUSA (826 United Kingdom of Great Britain and Northern Ireland), Petr DVOŘÁK (203 Czech Republic, guarantor, belonging to the institution), C. FREUND (528 Netherlands), M. FIRPO (840 United States of America), M.K. FURUE (392 Japan), P. GOKHALE (826 United Kingdom of Great Britain and Northern Ireland), H.Y. HA (410 Republic of Korea), E. HAN (410 Republic of Korea), S. HAUPT (276 Germany), L. HEALY (826 United Kingdom of Great Britain and Northern Ireland), D.J. HEI (840 United States of America), O. HOVATTA (752 Sweden), C. HUNT (826 United Kingdom of Great Britain and Northern Ireland), S.M. HWANG (158 Taiwan), M.S. INAMDAR (356 India), R.M. ISASI (124 Canada), M. JACONI (756 Switzerland), V. JEKERLE (826 United Kingdom of Great Britain and Northern Ireland), P. KAMTHORN (764 Thailand), M.C. KIBBEY (840 United States of America), I. KNEZEVIC (756 Switzerland), B.B. KNOWLES (764 Thailand), S.K. KOO (410 Republic of Korea), Y. LAABI (250 France), L. LEOPOLDO (724 Spain), P. LIU (826 United Kingdom of Great Britain and Northern Ireland), G.P. LOMAX (840 United States of America), J.F. LORING (840 United States of America), T.E. LUDWIG (840 United States of America), K. MONTGOMERY (840 United States of America), C. MUMMERY (528 Netherlands), A. NAGY (124 Canada), Y. NAKAMURA (392 Japan), N. NAKATSUJI (392 Japan), S. OH (702 Singapore), S.K. OH (410 Republic of Korea), T. OTONKOSKI (246 Finland), M. PERA (840 United States of America), M. PESCHANSKI (250 France), P. PRANKE (76 Brazil), K.M. RAJALA (246 Finland), M. RAO (840 United States of America), R. RUTTACHUK (764 Thailand), B. REUBINOFF (376 Israel), L. RICCO (724 Spain), H. ROOKE (840 United States of America), D. SIPP (840 United States of America), G.N. STACEY (826 United Kingdom of Great Britain and Northern Ireland), H. SUEMORI (392 Japan), T.A. TAKAHASHI (392 Japan), K. TAKADA (392 Japan), S. TALIB (840 United States of America), S. TANNENBAUM (376 Israel), B.Z. YUAN (156 China), F. ZENG (156 China) and Q. ZHOU (156 China).
Edition REGENERATIVE MEDICINE, LONDON, FUTURE MEDICINE LTD, 2015, 1746-0751.
Other information
Original language English
Type of outcome Article in a journal
Field of Study Genetics and molecular biology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.602
RIV identification code RIV/00216224:14110/15:00083494
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2217/RME.14.93
UT WoS 000349681900001
Keywords in English COPY NUMBER; MOLECULAR CYTOGENETICS; GENOMIC STABILITY; GENE-EXPRESSION; LINES; CULTURE; CRYOPRESERVATION; MUTATIONS; TERATOCARCINOMAS; STANDARDIZATION
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 3/8/2015 10:06.
Abstract
In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell Forum published a consensus on principles of best practice for the procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC) lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early seed stocks of stem cell lines intended for clinical applications. The term ‘seed stock’ is used here to describe those cryopreserved stocks of cells established early in the passage history of a pluripotent stem cell line in the lab that derived the line or a stem cell bank, hereafter called the ‘repository’.
PrintDisplayed: 6/6/2024 04:26